GILEAD SCIENCES, INC. Cash and Restricted Cash
GILEAD SCIENCES, INC. (GILD) had Cash and Restricted Cash of $3.18 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.18B.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.63B.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.56B.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.33B.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $3.18B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $7.63B 10-Q · filed 2026-05-07 |
| 2025-12-31 | $7.56B 10-Q · filed 2026-08-06 |
| 2025-09-30 | $7.33B 10-Q · filed 2025-11-07 |
| 2025-06-30 | $5.14B 10-Q · filed 2026-08-06 |
| 2025-03-31 | $7.93B 10-Q · filed 2026-05-07 |
| 2024-12-31 | $9.99B 10-Q · filed 2026-08-06 |
| 2024-09-30 | $5.04B 10-Q · filed 2025-11-07 |
| 2024-06-30 | $2.77B 10-Q · filed 2025-08-07 |
| 2024-03-31 | $4.72B 10-Q · filed 2025-05-07 |
| 2023-12-31 | $6.08B 10-K · filed 2026-02-24 |
| 2023-09-30 | $5.71B 10-Q · filed 2024-11-12 |
| 2023-06-30 | $5.70B 10-Q · filed 2024-08-08 |
| 2023-03-31 | $4.94B 10-Q · filed 2024-05-08 |
| 2022-12-31 | $5.41B 10-K · filed 2026-02-24 |
| 2022-09-30 | $4.70B 10-Q · filed 2023-11-07 |
| 2022-06-30 | $4.74B 10-Q · filed 2023-08-04 |
| 2022-03-31 | $4.30B 10-Q · filed 2023-05-03 |
| 2021-12-31 | $5.34B 10-K · filed 2025-02-28 |
| 2021-09-30 | $4.36B 10-Q · filed 2022-11-02 |
| 2021-06-30 | $4.89B 10-Q · filed 2022-08-08 |
| 2021-03-31 | $4.07B 10-Q · filed 2022-05-04 |
| 2020-12-31 | $6.00B 10-K · filed 2024-02-23 |
| 2020-09-30 | $12.89B 10-Q · filed 2021-11-03 |
| 2020-06-30 | $6.75B 10-Q · filed 2021-08-05 |
| 2020-03-31 | $10.05B 10-Q · filed 2021-05-06 |
| 2019-12-31 | $11.63B 10-K · filed 2023-02-22 |
| 2019-09-30 | $9.47B 10-Q · filed 2020-11-04 |
| 2019-06-30 | $11.24B 10-Q · filed 2020-08-06 |
| 2019-03-31 | $16.93B 10-Q · filed 2020-05-06 |
| 2018-12-31 | $17.94B 10-K · filed 2022-02-23 |
| 2018-09-30 | $14.57B 10-Q · filed 2019-11-05 |
| 2017-12-31 | $7.59B 10-K · filed 2021-02-25 |
| 2016-12-31 | $8.23B 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |